The Evolving Landscape in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Best Practice Clinical Applications of Current Evidence and New Guideline Recommendations

Learn how the experts individualize treatments and manage toxicities associated with established and emerging therapies in CLL/SLL in this program centered around a dynamic live symposium at ASCO 2023. Download slides, watch the on-demand webcast, and read an expert-authored commentary summarizing the key learning points from the live symposium, and download NCCN Guidelines for Patients® as a clinical resource for use in your clinic

Share

Program Content

Activities

Key Variables in Treating CLL/SLL
Individualizing the Care of Patients with CLL/SLL: Key Variables in Treatment-Decision Making
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2023

Relapsed or Refractory CLL
Effective Management of Patients with Relapsed/Refractory CLL/SLL
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2023

Newly Diagnosed CLL
Management of Patients with Newly Diagnosed CLL/SLL
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2023

Activities

FAQs: Refining CLL and SLL Tx
FAQs: Fine-tuning Contemporary Treatment for Patients With CLL/SLL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 21, 2023

Faculty

cover img faculity

Jeremy S Abramson, MD, MMSc

Director, Center for Lymphoma
Mass General Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Farrukh T Awan, MD, MS, MBA

Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

cover img faculity

Brian T Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Provided by

ProCE Banner

Provided by the National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca, BeiGene Ltd, and Lilly. Supported by independent educational grants from Merck & Co., Inc., Rahway, NJ, USA, and Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.

AstraZeneca

BeiGene, Ltd.

Janssen Biotech, Inc.

Lilly

Merck Sharp & Dohme Corp.

Pharmacyclics LLC, an AbbVie Company

Partners

Clinical Care Options, LLC

ProCE Banner